Related Experiment Videos
[Should hemostatic factors be considered in the prevention of cardiovascular disease?]
1II Katedry Chorób Wewnetrznych, Collegium Medicum, Uniwersytet Jagielloński, Kraków.
Insights
Atherosclerosis involves thrombosis, with endothelial injury triggering platelet activation. Understanding these links is crucial for developing optimal antithrombotic strategies in cardiovascular disease patients.
Area of Science:
- Cardiovascular Science
- Hematology
- Pathophysiology
Context:
- The interplay between thrombosis and atherosclerosis has been recognized for decades.
- Recent hypotheses highlight endothelial cell injury and platelet activation in atherogenesis.
- Cytokines, thrombin, and the fibrinolytic system are implicated in atherosclerotic lesion development.
Purpose:
- To explore the intricate relationship between thrombosis and atherosclerosis.
- To review the role of platelet activation, growth factors, and hemostatic factors in cardiovascular disease.
- To address the optimal antithrombotic strategy for patients with cardiovascular diseases.
Summary:
- Atherosclerosis pathogenesis involves chronic endothelial injury, platelet aggregation, and growth factor release.
- Lipoprotein (a), fibrinogen, factor VII, and plasminogen activator inhibitor-1 are emerging as key links between lipids, hemostasis, and ischemic heart disease.
- Thrombus formation underlies acute coronary syndromes, while antiplatelet agents offer protection.
Impact:
- This research informs the development of targeted antithrombotic therapies.
- Understanding these mechanisms can lead to improved prevention and management of cardiovascular events.
- Identifying key risk factors aids in personalized risk assessment and treatment strategies.
Abstract:
The relationship between thrombosis and atherosclerosis has been already suggested in the middle of the last century. More recently, in 1976 a hypothesis has been put forward which emphasize the leading role of chronic injury to endothelial cells followed by platelet attachment and the release of platelet derived growth factors in pathogenesis of atherosclerosis. There is also a growing body of evidence that cytokines, thrombin and the fibrinolytic system are involved in the initiation and progression of atherosclerotic lesions. Lipoprotein (a) is emerging as a link between atherogenic role of lipids and the haemostatic system. At the same time epidemiological data are pointing at the possible role of fibrinogen, factor VII and plasminogen activator inhibitor-1 as risk factors for ischemic heart disease. Thrombus formation is also responsible for the majority of acute coronary syndromes. On the other hand aspirin and other antiplatelet drugs seem to protect from vascular complications of atherosclerosis. Than the question which rather arises is: what is the best antithrombotic strategy in patients with cardiovascular diseases?